Recombinant Human IFNGR2 Protein, N-His from ProteoGenix; catalogue ARO-P11620; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Recombinant Human IFNGR2 Protein, also known as interferon gamma receptor 2, is a type II transmembrane protein that plays a crucial role in the immune response. It is a member of the cytokine receptor superfamily and is involved in the signaling pathway of interferon-gamma (IFN-γ), a key cytokine in the immune system. In this article, we will discuss the structure, activity, and applications of Recombinant Human IFNGR2 Protein.
The gene encoding IFNGR2 is located on chromosome 21 in humans and consists of seven exons. The protein is composed of 337 amino acids and has a molecular weight of approximately 37 kDa. It is composed of an extracellular domain, a transmembrane domain, and a cytoplasmic domain. The extracellular domain contains two fibronectin type III domains and is responsible for binding to IFN-γ. The transmembrane domain anchors the protein to the cell membrane, while the cytoplasmic domain is involved in signal transduction.
IFNGR2 is primarily expressed on the surface of immune cells such as T cells, B cells, and natural killer cells. It serves as a co-receptor for IFN-γ, which is produced by activated T cells and natural killer cells in response to viral or bacterial infections. When IFN-γ binds to IFNGR2, it triggers a signaling cascade that leads to the activation of various immune cells and the production of pro-inflammatory cytokines. This results in the recruitment of other immune cells to the site of infection and the elimination of pathogens.
Recombinant Human IFNGR2 Protein has various applications in both research and clinical settings. One of its main uses is in studying the role of IFN-γ signaling in the immune response. Researchers can use recombinant IFNGR2 protein to block the binding of IFN-γ to its receptor and study the downstream effects on immune cell activation and cytokine production.
In clinical settings, recombinant IFNGR2 protein has shown potential as a therapeutic agent for various diseases. For example, it has been studied for its potential use in treating chronic viral infections such as hepatitis B and C. By blocking IFN-γ signaling, it can prevent the excessive activation of immune cells, which can lead to tissue damage and disease progression.
Moreover, IFNGR2 has also been investigated as a potential target for cancer therapy. It has been found that some cancer cells overexpress IFNGR2, which allows them to evade immune surveillance. By targeting IFNGR2, it is possible to enhance the anti-tumor immune response and improve the efficacy of cancer treatments.
In summary, Recombinant Human IFNGR2 Protein is a key player in the immune response, functioning as a co-receptor for IFN-γ. Its structure, activity, and applications make it a valuable tool in both research and clinical settings. Further studies on this protein may lead to a better understanding of the immune system and the development of new therapies for various diseases.
ProteoGenix catalogue number ARO-P11620. For research use only.
Host: Escherichia coli (E.coli); Expression system: Prokaryotic expression; Molecular weight: 25.41 kDa; Fragment: Lys37-Asp240; Buffer: Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol..
Available configurations: 50ug, 100ug, 1mg.
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
